I-MAB Says Will Continue To Review Follow-Up Data From The Phase 2 Study Of Lemzoparlimab In HR-MDS; AbbVie Terminating Agreement Relating To Certain CD47 Antibody Compounds And Products
Portfolio Pulse from Benzinga Newsdesk
I-MAB announced it will continue to review follow-up data from the Phase 2 study of Lemzoparlimab in HR-MDS. Meanwhile, AbbVie is terminating its agreement related to certain CD47 antibody compounds and products.
September 22, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
I-MAB's decision to continue reviewing data from the Phase 2 study of Lemzoparlimab could potentially impact its stock positively if the results are favorable.
I-MAB's decision to continue reviewing data from the Phase 2 study of Lemzoparlimab indicates that the company sees potential in the drug. If the results are favorable, it could lead to a positive impact on the company's stock. However, the impact is uncertain until the results are disclosed.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
AbbVie's termination of its agreement related to certain CD47 antibody compounds and products could potentially have a negative impact on its stock.
AbbVie's decision to terminate its agreement related to certain CD47 antibody compounds and products could be seen as a negative development by investors, potentially leading to a negative impact on the company's stock. However, the overall impact will depend on the importance of this agreement to AbbVie's business.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70